US EditionPublished • loading... • Updated
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans
Biogen (NASDAQ:BIIB) executives highlighted progress across several pipeline programs during a discussion that focused on the company’s tau antisense oligonucleotide (ASO) program in Alzheimer’s disease, pre-symptomatic anti-amyloid studies, neuromuscular development in spinal muscular atrophy (SMA), and immunology assets in lupus and kidney diseases. Tau ASO program: rationale, safety considerations, and the CELIA trial Diana Gallagher, […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
